This class includes semaglutide (Ozempic for diabetes, Wegovy for weight management) and liraglutide (Victoza for diabetes, Saxenda for weight management)
FDA relies on the complete, accurate, and timely submission of ADEs to monitor a products safety profile and uphold FDAs mission to protect and promote public health, the FDA wrote, referring to adverse drug events. It said findings were based on an inspection of a Novo Nordisk facility in New Jersey last year
Get Real Results
Over-the-Counter Remedies Nonprescription options can complement lifestyle changes, provided you check interactions with your clinician first
If you experience any adverse effects from medication, report them through the MHRA Yellow Card scheme
The FDA recently sent Novo Nordisk a Complete Response Letter (CRL) for Tresiba and Ryzodeg (Ryzodeg is a mixture of 70% Tresiba and 30% Novolog), asking for a pre-approval cardiovascular outcomes trial (CVOT) to show if the insulin has an unacceptable safety risk for heart disease